A recent phase III clinical trial found that a combination of chidamide and exemestane has therapeutic potential for postmenopausal patients with advanced, hormone receptor-positive (HR+), HER2– breast cancer and who have failed to respond to endocrine therapy (Jiang et al., 2019). Here, NR4A1 is linked to breast carcinoma.